Drug company merger should benefit research
نویسندگان
چکیده
منابع مشابه
Reinvigorating the concept of benefit: the failure of drug company-sponsored research on human subjects.
In the early 1970s, Congress directed the Secretary of Health, Education and Welfare to create a commission for the purpose of ascertaining the important principles that should guide biomedical research that uses human research subjects. The report of this commission was to be published by the Secretary in the Federal Register and, unless the Secretary made any other proposals, it was to become...
متن کاملShould benefit–risk assessment have its own drug “label”?
Many consumers and clinicians incorrectly believe that the Food and Drug Administration (FDA) approval of a new therapeutic implies that its benefits have been proven to exceed its harms. While the FDA could require proof that benefits exceed harms prior to approval, it has been argued that this approach would be infeasible because of prohibitively large sample sizes. One possible alternative w...
متن کاملStealth merger: drug companies and government medical research.
Dr. Salk's professional life was as far removed from that oftoday's researchers at the National Institutes ofHealth as the sun is from, say, Wall Street. Theoretically, the NIH belongs to the American people. U.S. taxpayers give it $28 billion a year to develop remedies for human misery. Many assume that today's NIH researchers are carrying on the mission as Salk did, free from financial or com...
متن کاملWhat should regulators do about merger policy?
I argue that merger policy needs to be driven by dierent considerations in Europe, Japan and the United States. In Europe the main challenge is to set up a system so that ecient consolidation can occur once the single currency is established. In Japan the policy ought to be directed towards trying to attract foreign institutions to acquire under-capitalized domestic institutions. Japan does n...
متن کاملRegulating Bioprospecting: Institutions for Drug Research, Access and Benefit-Sharing
T policy brief summarizes the main arguments and conclusions of a forthcoming book by United Nations University Press, which examines the regulation of bioprospecting for drug research from an interdisciplinary law and economics perspective. Bioprospecting was once touted as a promising opportunity for collaborative ventures in biotechnology-based research and development (R&D) between the gene...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1998
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.316.7130.493c